Fed. Circ. Says Sandoz Attack On Amgen Patents Is Premature
The Federal Circuit on Friday ruled that Sandoz Inc.'s lawsuit to invalidate patents for Amgen Inc.'s biologic arthritis drug Enbrel was too early to create jurisdiction in courts, upholding a decision...To view the full article, register now.
Already a subscriber? Click here to view full article